NLP-Based feedback to improve shared decision making for men with localized prostate cancer
Natural Language Processing-Based Feedback to Improve Physician Risk Communication and Informed Shared Decision Making in Men With Clinically Localized Prostate Cancer
This trial will test an NLP+AI risk-communication feedback tool for doctors and men with newly diagnosed localized prostate cancer to see if it improves how treatment risks and tradeoffs are discussed and supports better decisions.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 283 (estimated) |
| Ages | 18 Years and up |
| Sex | Male |
| Sponsor | Cedars-Sinai Medical Center Academic / other |
| Drugs / interventions | Radiation |
| Locations | 1 site (Los Angeles, California) |
| Trial ID | NCT06856694 on ClinicalTrials.gov |
What this trial studies
This cluster randomized trial will enroll about 259 men with clinically localized prostate cancer seen by 24 participating physicians at Cedars-Sinai. Physician clusters are randomized to usual care with AUA-endorsed educational materials or to an experimental arm where patients and physicians receive an NLP+AI-generated feedback report about key tradeoffs discussed within ~72 hours of the consultation. The report highlights what was said about risks and benefits and provides graded feedback to physicians on shared decision making. Study outcomes include quality of risk communication and measures of patient decision making.
Who should consider this trial
Good fit: Ideal participants are English-speaking men undergoing an initial treatment consultation for newly diagnosed clinically localized prostate cancer or those on active surveillance considering conversion to definitive local therapy.
Not a fit: Patients who are non-English speakers, have locally advanced or metastatic disease, have already been treated for localized prostate cancer, have significant communication impairment or dementia, or are under 18 are unlikely to benefit from this study.
Why it matters
Potential benefit: If successful, the tool could make discussions about treatment risks clearer and help patients make more informed, confident choices.
How similar studies have performed: Related NLP and AI tools for clinical communication have shown promising pilot results, but few randomized trials have yet demonstrated clear improvements in patient decision outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Physician Inclusion Criteria (1) Physicians who typically counsel prostate cancer patients (Urology, Radiation Oncology, Medical Oncology) Patient Inclusion Criteria 1. Patients undergoing initial treatment consultation for clinically localized prostate cancer; 2. Patients with upgraded prostate cancer on active surveillance considering conversion to definitive local therapy; 3. Ability to read and write in English. Patient Exclusion Criteria: 1. Under 18 years of age; 2. Subjects with difficulty communicating or dementia; 3. Non-English speakers, given that our NLP-based tools cannot be used with languages other than English; 4. Patients with locally advanced or metastatic prostate cancer; 5. Patients who have already been treated for clinically localized prostate cancer.
Where this trial is running
Los Angeles, California
- Cedars Sinai Medical Center — Los Angeles, California, United States (Recruiting)
Study contacts
- Study coordinator: Timothy Daskivich, MD
- Email: Timothy.Daskivich@cshs.org
- Phone: 310-423-4700
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.